StreetAlpha.app
Home › Stocks › RVMD

Revolution Medicines, Inc. (RVMD)

Healthcare
$161.20
▲ +1.11%
LAST CLOSE · NOV 20

Revolution Medicines develops cancer drug candidates from its base in Redwood City, California. It last closed at $161.20 on Nov 20, up 1.11% on the day. The next earnings report for RVMD is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, RVMD reported EPS of -$1.90 on revenue of $197.6M. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months RVMD insiders bought $0 of stock on the open market and sold $160.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is RVMD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RVMD.

Key Stats

Last 12 months
Results
Revenue
$197.6M
Net income
−$1.9B
−946.8% margin
EPS (diluted)
−$9.13
Free cash flow
−$1.4B
−729.3% margin
Valuation
Market cap
$34.9B
216.3M shares
P/E
–
No P/E while losing money
Price to sales
176.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$615.9M
At Sep 30
Debt
$487.9M
At Sep 30
Shareholder equity
$2.4B
Shares outstanding
216.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $29.4M$29.4MFY2021FY2022: $35.4M$35.4MFY2022FY2023: $11.6M$11.6MFY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From RVMD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
-$1.90
Quarter ended Sep 2026
Year ago EPS
-$1.61
Same quarter last year
Revenue
$197.6M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.13Dec '24Mar 2025: -$1.13Mar '25Jun 2025: -$1.31Jun '25Sep 2025: -$1.61Sep '25Dec 2025: -$1.89Dec '25Mar 2026: -$2.29Mar '26Jun 2026: -$3.06Jun '26Sep 2026: -$1.90Sep '26Latest -$1.90
Revenue by quarter
Dec 2024: $0Dec '24Sep 2025: $0Sep '25Dec 2025: $0Dec '25Sep 2026: $197.6MSep '26Latest $197.6M
How RVMD moved after its last 8 reports
Average move the session after a report ±5.1%
Nov 4, 2026After the close−11.0%
Aug 5, 2026After the close+0.3%
May 6, 2026After the close−5.7%
Feb 25, 2026After the close−1.1%
Nov 5, 2025After the close+3.4%
Aug 6, 2025After the close−4.7%
May 7, 2025After the close+11.3%
Feb 26, 2025After the close−3.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RVMDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RVMD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RVMD

Technical Analysis

RVMD · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 12% below its 20 day and 18% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $157.78, and the nearest resistance the 200 day average at $161.51.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.8%/day
Key levels
$224.3152 week high+39.2%
$194.13100 day average+20.4%
$190.0250 day average+17.9%
$181.2520 day average+12.4%
$167.07Pivot R1+3.6%
$166.50Swing high (Jun 1)+3.3%
$163.64Pivot+1.5%
$161.51200 day average+0.2%
$161.20Last close
$157.78Pivot S1−2.1%
$149.10Swing low (May 28)−7.5%
$69.5052 week low−56.9%
Indicators
RSI (14)35.59Weak, oversold below 30Neutral
MACD-8.40Below its signal lineBearish
Stochastic3.4Near the bottom of its rangeOversold
ADX (14)24.1Weak trend
Williams %R-94.6Oversold below −80, overbought above −20Oversold
CCI (20)-116.3Oversold below −100, overbought above 100Oversold
Rate of change−16.2%Change over 10 sessionsBearish
ATR (14)$9.29Typical daily range, 5.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RVMD

What happened before

See how RVMD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RVMD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RVMD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RVMDHow many large options trades hit RVMD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RVMD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲455 buying vs 270 selling
  • ▼Held by funds -0.7 pts
  • ▲Funds holding +66
  • ▲Superinvestors: 3 added, 1 cut
  • ▼Put/call 0.52 to 1.13
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding761695+9.5%
In funds' top 103747−21.3%
Held by funds98.3%99.0%−0.7 pts
New / increased143 / 312237 / 242−5.0%
Reduced / sold out198 / 72149 / 64+26.8%
Put/call ratio1.130.52+115.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RVMD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RVMD Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$160.1M53 sales · 12 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $2.4M2026-01 sold $8.6M2026-03 sold $10.4M2026-04 sold $18.4M2026-05 sold $481K2026-06 sold $24.6M2026-08 sold $41.3M2026-09 sold $36.7M2026-10 sold $432K2026-11 sold $11.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Stephen Michael KelseySee RemarksSale plan27,160$167.86$4.6M
Nov 11Jack AndersCFOSale plan35,750$188.10$6.7M
Nov 9Anthony ManciniSee RemarksSale plan811$200.00$162K
Oct 26Anthony ManciniSee RemarksSale plan2,310$186.99$432K
Sep 29Alan B. SandlerChief Development OfficerSale plan6,309$202.14$1.3M
Sep 25Jeff CisliniSVP & General CounselSale plan765$207.32$159K
Every insider buy and sale for RVMD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RVMD insider trades →

From SEC Form 4 filings by RVMD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RVMD is in one of them and how their past RVMD trades turned out.

RVMD in the AI portfolios
Loading…

RVMD News Tone and Price

Loading…

RVMD News & Analysis

All StreetAlpha news →
RVMD in the news

About Revolution Medicines

Revolution Medicines is a biotechnology company based in Redwood City, California. It is developing drug candidates for cancer, including RAS(ON) inhibitors, which are being tested alone and in combination with other cancer therapies. None of its product candidates has received regulatory approval yet, so it does not currently sell products. Its work is aimed at cancer patients and the doctors who treat them.

Headquarters
Redwood City, CA
Founded
2014